BWXT — BWX Technologies
March 2026 update merged from catalyst monitor. See also bwxt-filings for Q4 2025 / FY2025 detail. Adjacent coverage in SMR-Companies-Comparative-Stock-Analysis and SMR-Reactor-Designs-Comprehensive.
Identity
- Company: BWX Technologies, Inc.
- Ticker: BWXT (NYSE)
- Sector: Nuclear / Defense
- Business: Naval nuclear reactors, nuclear fuel, medical radioisotopes, advanced nuclear technologies
- Stock: ~$210 (Mar 2026) | 52-Week Range: $84.21–$220.57 | Market Cap: ~$19.3B
Thesis
Nuclear will accelerate. BWXT is the dominant US naval nuclear reactor manufacturer — sole-source supplier to the US Navy for Virginia-class, Columbia-class, and Ford-class. Also positioned for commercial SMR buildout (Project Pele microreactor, BANR), TRISO fuel production (sells to all SMR competitors), and medical isotopes (BWXT Medical >$100M annual revenue, growing 20%).
The competitive moat — sole-source naval nuclear + TRISO fuel leadership — is about as wide as it gets in defense. Q4 2025 was a beat-and-raise; backlog hit a record $7.3B (+50% YoY); 2026 guidance came in above consensus across the board.
The valuation question: 57x P/E vs 40x peer average vs DCF fair value of ~$92. The market is paying for sustained high-teens growth for years. Any deceleration in contract awards or margin compression from new program ramps could trigger a pullback. But the structural demand picture — defense spending, nuclear renaissance, AUKUS, microreactors, medical isotopes — is as strong as it's been in decades.
Business
Government Operations (FY2025: $2,350M revenue, +8% YoY, $5.5B backlog +41%)
Naval nuclear reactors and fuel for US Navy submarines and aircraft carriers. Sole-source supplier. Bedrock segment.
Commercial Operations (FY2025: $853M revenue, +63% YoY, $1.7B backlog +85%)
Kinectrics acquisition was the big driver — closed May 2025 for $525M, nearly doubled commercial workforce. Adds lifecycle management services for nuclear power and T&D, plus radiopharmaceutical isotopes. Commercial Ops also covers field services, fuel, components, medical isotope sales.
BWXT Medical
Surpassed $100M annual revenue in FY2025, +20% YoY. Diagnostic isotopes (Mo-99 → Tc-99m generators via Laurentis Energy Partners / OPG Darlington partnership), TheraSphere therapeutic, NextGen MURR Owner's Engineer services for U-Missouri research reactor. APAC JV with Global Medical Solutions. Policy tailwind: $10 add-on payment for radiopharmaceuticals from domestic Mo-99 starting Jan 2026. FDA decision pending on Tc-99m generator.
Recent contract awards
- $2.6B Naval Nuclear (Jul 2025) — Virginia-class, Columbia-class subs + Ford-class carrier components, 6–8 year delivery
- $174M Naval Nuclear Fuel (Sep 2025) — work commenced, target completion summer 2026
- $1.5B NNSA DUECE (Sep 2025) — Domestic Uranium Enrichment Centrifuge Experiment pilot plant. Establishes domestic uranium enrichment for defense. Strategic win.
- $1.6B High-Purity Depleted Uranium — special materials processing
- FY2025 total bookings: $5.4B, book-to-bill well above 1.0x
Programs
Project Pele (DoD Microreactor — sole prime contractor)
US military's first transportable microreactor.
- Aug 2025: started building Pele core at Lynchburg
- Dec 2025: full TRISO fuel core delivered to Idaho National Lab
- Formal system testing as early as 2027
- Electricity production at INL targeted as soon as 2028
BANR (BWXT Advanced Nuclear Reactor)
50 MWt high-temperature gas reactor, TRISO fuel, helium coolant. Factory-built, transportable by rail/ship/truck. LOI with Tata Chemicals to explore deploying up to 8 BANRs at a soda ash mining site in Green River, Wyoming. No NRC permit application filed yet — commercial timeline undefined. Not rushing because submarine work is more profitable.
TRISO Fuel Production
Completed advanced TRISO manufacturing equipment installation in Virginia (Jul 2025). Now producing commercial quantities. Supplies multiple competing SMR designs (X-energy, etc.) — BWXT wins regardless of which design succeeds.
DRACO (NASA/DARPA Nuclear Thermal Propulsion)
JV providing fuel and reactor design for in-space demonstration of nuclear thermal rocket engine. Work based at Innovation Campus.
Innovation Campus
170,000 sq ft Lynchburg, VA facility opened March 2025. Houses Advanced Technologies unit (350+ team). $51M invested through end-2024. Hub for Pele, BANR, DRACO, commercial advanced reactor work.
Acquisitions
Kinectrics — $525M (closed May 2025)
Lifecycle management for global nuclear power and T&D markets, plus radiopharmaceutical isotopes. Nearly doubled Commercial Ops workforce.
- Watch item: Canada's Competition Bureau expanded its investigation Nov 2025 into whether the deal lessens competition in Canadian nuclear medicine. Investigation ongoing.
A.O.T. (2025)
Smaller bolt-on. Contributing to Government Ops growth via higher special materials processing.
Management
- Rex Geveden — CEO. Q4 2025 quote: "We delivered a strong fourth quarter, and a record year for BWXT. We operate at the intersection of national security and commercial nuclear power markets, where demand for both remains exceptionally strong."
- Kevin M. McCoy — Chief Nuclear Officer (supporting Columbia/Virginia sub production acceleration)
- Joe Miller — President, Government Operations (promoted)
- Kate Kelly — President, Advanced Technologies (promoted)
- Kurt Bender — SVP & Chief Digital Officer (eff. Feb 5, 2026)
- Dan Jablonsky — Director (eff. Mar 2, 2026), Audit & Finance committee
- Insider activity: Standard RSU/option compensation. Director Burbach sold 1,983 shares ($413K) Feb 27, 2026. No major buying or unusual selling.
Compensation signal — May 2025 special CEO grant ("confidence grant" per Tarot Capital)
On May 7, 2025, the Board approved a special equity grant to CEO Rex Geveden, target value $5.5M, in two structured components — both cliff-vesting December 31, 2027:
| Component | Grant-date value | Performance period | Hurdle | Payout range |
|---|---|---|---|---|
| PSUs | $2.2M | Jan 1, 2025 – Dec 31, 2027 | 50% cumulative revenue + 50% EBITDA margin expansion | 0–150% per metric |
| NQPSOs | $3.3M | May 7, 2025 – Dec 31, 2027 | Total shareholder return vs S&P Aerospace & Defense Select Index (XAR) | 0–150% |
Why this matters — Tarot Capital's read (post May 23, 2025; archived at KB/raw/substack-archive/tarot-capital/2025-05-23-bwxt-confidence-grant.md):
- The PSU performance period started 1/1/2025 — before the grant date. That means the Board wrote the revenue + EBITDA hurdles already knowing Q1 2025 actuals and most of Q2 2025. They wouldn't set targets they didn't believe were already on track. Tarot classifies this as a "confidence grant" — directionally optimistic, not just compensation rebalancing.
- The XAR hurdle is the loaded one. Management is explicitly being paid to outperform the traditional defense complex (LMT, NOC, RTX, etc.) over 2.5 years. The thesis embedded in the grant: BWXT's faster top-line growth + accelerating FCF conversion (toward management's 90% target) + backlog growth should translate to TSR alpha vs. legacy primes.
- No explicit price target in the post, but the implicit framework: if BWXT clears the XAR hurdle through Dec 31, 2027 + hits the 150% PSU max on revenue and EBITDA expansion, the equity tape should be strong over that window.
Read-through for current position management: This grant is independent corroboration that management sees multi-year tape, not just a quarterly cycle. Aligns with FY revisions trending higher (+7% over 90d as of May 2026) and the 4-for-4 ~22% beat history. The grant period still has ~19 months left (as of May 2026) — the "tailwinds to the equity" framing remains live.
Financials snapshot (FY2025)
- Revenue $3,198M (+18%)
- Adj EBITDA $574.3M (+15%)
- Non-GAAP EPS $4.01 (+20%)
- FCF $295.3M (+16%)
- Backlog $7.3B (+50%)
- Bookings $5.4B (+51%)
- Dividend +8% to $0.27/qtr — 11 consecutive years of dividend growth, payout ratio ~30%
2026 Guidance (above consensus across the board)
- Revenue ~$3.75B (consensus $3.67B)
- Adj EBITDA $645–660M
- Non-GAAP EPS $4.55–4.70 (consensus $4.30)
- FCF $305–320M
- Govt Ops: low-to-mid teens revenue growth
- Commercial Ops: ~25% revenue growth
- ~55% of EBITDA in H2 (back-half weighted)
- Govt margins "slightly lower" early in new programs, rebound in 2027
Valuation & analyst coverage
- P/E: 57–58x (vs peer avg 40.5x, A&D industry 39.6x)
- Simply Wall St fair P/E estimate: 34.6x — expensive on traditional metrics
- DCF fair value: ~$92 (way below market — implies massive growth pricing)
- Bull case fair value: $220 (community narrative)
- Revenue growth 13.2% annualized over 2 years; FCF margins improving
- TD Securities/TD Cowen initiated Buy with $230 PT (Mar 12, 2026, Marc Bianchi). Thesis: "Strong nuclear heritage," technology-agnostic service model, multiple growth opportunities that could translate to >$10B of value
- Consensus (Mar 2026): 14 analysts, 7 Buy, 5 Hold, 0 Sell. Median PT $225, range $182–$290
- BofA (Epstein): Buy — upside from AUKUS, acquisitions, aftermarket
- Northland Securities (Grampp): raised FY2026 EPS estimate to $4.61
Stock performance
| Period | Return |
|---|---|
| 2024 | +47% |
| 2025 | +55% |
| 2026 YTD | +10% |
| 1-Year TSR | +98% |
| 90-Day | +15% |
Trading near 52-week high of $220.57. Above 200-day SMA. More than tripled from 52-week low.
Catalysts to watch
Near-term (2026)
- Q1 2026 earnings (May) — first quarter under new guidance framework
- Project Pele construction milestones
- Canada Competition Bureau ruling on Kinectrics
- TRISO fuel production ramp + customer announcements
- FDA decision on Tc-99m generator
- BANR NRC engagement or customer announcements
Medium-term (2026–2028)
- Project Pele electricity production at INL (2028 target)
- BANR commercial deployment (Tata Chemicals LOI)
- Kinectrics integration + margin expansion
- AUKUS-driven US submarine production acceleration
- Columbia-class submarine delivery milestones
- Nuclear medicine revenue scaling past $100M base
Policy & regulatory environment
- FY2026 NDAA (signed Dec 18, 2025): $900.6B for DoD + DOE nuclear security, ~$8B above presidential request. Creates "holistic strategy to support US nuclear industry leadership." International Nuclear Energy Act of 2025 §8366 establishes Nuclear Export Working Group, $15.5M/year FY2026–2030.
- ADVANCE Act implementation: May 2025 EOs reformed nuclear reactor testing at DOE, ordered advanced reactor deployment for national security, streamlined NRC licensing for advanced reactors and microreactors.
- FY2026 Budget: DOE "reoriented around nuclear and hard infrastructure." Navy shipbuilding budget supports Columbia/Virginia.
- AUKUS: Australia announced $310M (Feb 2026) for long-lead items for nuclear propulsion from UK; $3.9B for AUKUS sub yard at Osborne SA. Key clarification: Rolls-Royce Submarines (UK) is the primary AUKUS propulsion contractor, not BWXT directly. BWXT benefits indirectly via increased US naval industrial base demand and potential involvement in US sub sales to Australia (Virginia-class in 2030s).
Competitive landscape
- Rolls-Royce SMR — won UK GBN SMR competition (Jun 2025), 3 SMRs with Great British Energy-Nuclear, downselected by Vattenfall alongside GE Hitachi BWRX-300, primary AUKUS contractor
- GE Hitachi (BWRX-300) — OPG construction approval at Darlington (Apr 2025), CAD $7.7B, target 2029. Vattenfall Sweden. UK GDA Step 2.
- NuScale — only SMR with NRC design certification. 6 GW deployment with ENTRA1 + TVA (Sep 2025). VOYGR plant Romania 2029. Not selected in UK GBN — setback.
- X-energy — 150 MWe TRISO fluoride salt-cooled reactor. Construction expected 2026 at Dow Chemical Texas, ops 2029. BWXT supplies the TRISO fuel — wins either way.
BWXT moat: sole-source US Navy reactor mfg + leading TRISO fuel producer (supplies competitors) + decades of operational nuclear experience + $7.3B backlog visibility + design-agnostic.
Decision log
- 2026-03-25 — Catalyst monitor compiled. Beat-and-raise quarter, record backlog, above-consensus guide. Stock at ~$210 trades at 57x P/E. Structural tailwinds intact, but valuation prices in perfect execution. Watch Q1 2026 earnings (May) for first read under new guidance framework.
Topics
- nuclear-smr
- defense-technology
- critical-minerals
- green-finance